Prio Wealth Limited Partnership lowered its stake in Danaher Co. (NYSE:DHR) by 2.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 65,356 shares of the conglomerate’s stock after selling 1,508 shares during the quarter. Prio Wealth Limited Partnership’s holdings in Danaher were worth $6,449,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of DHR. Mount Yale Investment Advisors LLC bought a new stake in shares of Danaher during the 1st quarter valued at about $103,000. IMS Capital Management bought a new stake in shares of Danaher during the 2nd quarter valued at about $107,000. BerganKDV Wealth Management LLC bought a new stake in shares of Danaher during the 2nd quarter valued at about $111,000. Zions Bancorporation bought a new stake in shares of Danaher during the 1st quarter valued at about $123,000. Finally, Kaizen Advisory LLC boosted its position in shares of Danaher by 150.3% during the 2nd quarter. Kaizen Advisory LLC now owns 1,464 shares of the conglomerate’s stock valued at $144,000 after acquiring an additional 879 shares during the last quarter. Institutional investors and hedge funds own 76.51% of the company’s stock.
A number of brokerages have recently issued reports on DHR. Zacks Investment Research downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. Royal Bank of Canada lifted their price target on Danaher to $107.00 and gave the company a “positive” rating in a research report on Thursday, July 19th. They noted that the move was a valuation call. ValuEngine downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Thursday, June 21st. Barclays reiterated a “buy” rating and set a $113.00 price target on shares of Danaher in a research report on Friday, April 20th. Finally, Morgan Stanley lifted their price target on Danaher from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, July 20th. Two research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $108.31.
Danaher (NYSE:DHR) last announced its quarterly earnings data on Thursday, July 19th. The conglomerate reported $1.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.06. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.91 billion. Danaher had a return on equity of 11.55% and a net margin of 13.84%. Danaher’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm posted $0.99 EPS. equities analysts expect that Danaher Co. will post 4.49 earnings per share for the current year.
In related news, CFO Daniel L. Comas sold 77,407 shares of the firm’s stock in a transaction dated Thursday, July 26th. The stock was sold at an average price of $103.93, for a total transaction of $8,044,909.51. Following the transaction, the chief financial officer now directly owns 135,218 shares of the company’s stock, valued at approximately $14,053,206.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Thomas Patrick Joyce, Jr. sold 104,913 shares of the firm’s stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of $101.88, for a total value of $10,688,536.44. Following the transaction, the insider now directly owns 276,438 shares in the company, valued at $28,163,503.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 196,875 shares of company stock worth $20,246,147. 11.90% of the stock is currently owned by insiders.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.